Study Data from University of Cambridge Provide New Insights into Multiple Sclerosis (Outcomes, complications, and dosing of intrathecal baclofen in the treatment of multiple sclerosis: a systematic review).

A systematic review conducted by researchers at the University of Cambridge evaluated the effectiveness of intrathecal baclofen (ITB) in treating multiple sclerosis-related spasticity (MSRS). The review analyzed studies published between 2000 and 2023 and found evidence supporting the effectiveness of ITB in treating MSRS patients who did not respond to oral medications. The treatment was shown to reduce spasm frequency and improve patients' quality of life. Complications were primarily surgical rather than pharmacological, and the average 1-year dose of ITB was lower than doses reported for other conditions. The review concludes that ITB is a clinically effective treatment for MSRS when other treatments have failed. [Extracted from the article]